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EXTL2 and EXTL3 inhibition with 
siRNAs as a promising substrate 
reduction therapy for Sanfilippo C 
syndrome
Isaac Canals1,2,3, Noelia Benetó1,2,3, Mónica Cozar1,2,3, Lluïsa Vilageliu1,2,3,* & 
Daniel Grinberg1,2,3,*
Sanfilippo syndrome is a rare lysosomal storage disorder caused by an impaired degradation of 
heparan sulfate (HS). It presents severe and progressive neurodegeneration and currently there is 
no effective treatment. Substrate reduction therapy (SRT) may be a useful option for neurological 
disorders of this kind, and several approaches have been tested to date. Here we use different 
siRNAs targeting EXTL2 and EXTL3 genes, which are important for HS synthesis, as SRT in 
Sanfilippo C patients’ fibroblasts in order to decrease glycosaminoglycan (GAG) storage inside the 
lysosomes. The results show a high inhibition of the EXTL gene mRNAs (around 90%), a decrease 
in GAG synthesis after three days (30–60%) and a decrease in GAG storage after 14 days (up to 
24%). Moreover, immunocytochemistry analyses showed a clear reversion of the phenotype after 
treatment. The in vitro inhibition of HS synthesis genes using siRNAs shown here is a first step in the 
development of a future therapeutic option for Sanfilippo C syndrome.
Sanfilippo C syndrome, or mucopolysaccharidosis (MPS) IIIC, is an autosomal recessive lysosomal stor-
age disorder caused by mutations in the HGSNAT gene. This gene codes for an enzyme responsible for 
heparan sulfate (HS) degradation, and its dysfunction leads to the storage of partially degraded mole-
cules inside the lysosomes1. HS is one of the most common glycosaminoglycans (GAGs) located in the 
extracellular matrix as a part of proteoglycans, which participate in many different cellular functions2. 
In the synthetic pathway of HS, there is an essential step in which the EXTL genes play a crucial role 
(reviewed in Ref. 3). In particular, EXTL2 and EXTL3 are key proteins involved in the HS chain elonga-
tion. Small interference RNAs (siRNAs), discovered in the late 1990s4, were shown to inhibit mammalian 
genes5, and may be applicable in substrate reduction therapy (SRT) for Sanfilippo C patients. For other 
types of MPS, two different approaches using siRNAs or shRNAs have been previously described which 
inhibit different genes in the HS synthetic pathway6,7.
In this study we used four different siRNAs, two of which inhibit EXTL2 and the other two inhibit 
EXTL3. These siRNAs were transfected into fibroblasts of two patients in an attempt to reduce HS syn-
thesis. All four siRNAs obtained a notable reduction in the mRNA levels of the corresponding gene and 
decreased the rates of GAG synthesis and storage.
Materials and Methods
Fibroblasts from two patients were used in this study: patient SFC6 (genotype: c.633+ 1G > A/p.L445P) 
and patient SFC7 (genotype: c.372-2A > G/c.372-2A > G). The patients and the culture conditions were 
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described in a previous work8. Fibroblasts were transfected with four different siRNAs using Lipofectamine 
2000 as the transfection agent. Quantities of 5, 2.5 and 1.25 μ l were used for 6-well, 12-well and 24-well 
plates respectively. Two Silencer® Select siRNAs (Ambion) for EXTL2 (si4899 and si4900), two for 
EXTL3 (si4901 and si4902) and one negative control (siC-) were used at a final concentration of 10 η M. 
siRNA sequences are available on demand. Quantitative real-time PCR was performed using TaqMan® 
Gene Expression Assays for EXTL2, EXTL3, HPRT and SDHA genes, the last two as endogenous controls. 
PCRs were carried out in a LightCycler® 480 System (Roche). For every assay, the efficiency (E) of the 
reaction was calculated from a 7 points standard curve. The reaction efficiency was taken into account 
in the quantification cycle (Cq) calculation using LightCycler® 480 Software (release 1.5.0) (Roche). To 
confirm precision and reproducibility of real-time PCR the intra-assay precision was determined in 3 
repeats within one LightCycler run. In the working conditions, the intra-assay coefficient of variation of 
all the assays at the working conditions was less than 1% and Cq standard deviation was smaller than 0.3.
The efficiency of GAG synthesis was quantified testing the cell incorporation of 35S sodium sulfate 
from the medium as previously described6. The sulfated GAG storage was quantified using the 
Rheumera® Proteoglycan Detection Kit (Astarte Biologics) following the manufacturer’s instructions. 
GAG extraction was performed as previously described9.
For heparan sulfate immunostainig, fibroblast cultures (untreated or treated as indicated above) were 
fixed in 4% PFA. Antibodies used were mouse anti-human HS (#H1890, 10E4 epitope, monoclonal 
antibody, USBiological) as a primary antibody, and donkey anti-mouse Cy2 (#715-225-150, polyclonal 
antibody, Jackson ImmunoResearch), as secondary antibody. For nucleus staining DAPI (Invitrogen) 
at 0.5 μ g/ml was used. The slides were mounted with PVA:DABCO mounting medium. Images were 
acquired with a Leica DMIRB fluorescence microscope and analyzed with the Fiji software10.
All experimental protocols were approved by the Ethics Committee of the University of Barcelona and 
were conducted under the Declaration of Helsinki. Patients were encoded to protect their confidentiality, 
and informed consent obtained.
Results
Inhibition of EXTL2 and EXTL3 mRNA with specific siRNAs. All EXTL siRNAs were tested in 
fibroblasts from both patients and high inhibition levels were observed from day 3 to day 14 after trans-
fection. All treated cells had expression levels of around 10% compared to cells treated with negative 
control siRNAs using SDHA as endongenous gene (Figure S1). Similar results were obtained with HPRT 
as endogenous gene (not shown).
Decrease in GAG synthesis. After three days of transfection, fibroblasts showed a decrease in the 
incorporation of 35S sulfate of about 30% to 60% (depending on the siRNA used) compared to control 
samples (Fig. 1). Both patients showed similar results for each siRNA, indicating a more efficient inhi-
bition of GAG synthesis for siRNAs designed to target the EXTL2 gene (more than 50%) than in those 
targeting the EXTL3 gene (less than 50%).
Figure 1. Inhibition of GAG synthesis. SFC6 and SFC7 fibroblasts were transfected with all four siRNAs 
and a negative control siRNA and after 3 days incorporation of 35S sodium sulfate was analysed. Results 
for both patients are the mean ± standard error of three experiments performed in quadruplicate and are 
expressed as disintegrations per minute per μ g of DNA. Differences between EXTL siRNAs with respect 
to negative control siRNA were evaluated using the non-parametric Mann-Whitney U test, and statistical 
significance was set at p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***).
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Decrease in GAG storage. Sulfated GAG storage was quantified in patients’ fibroblasts after treat-
ment (Fig. 2). After three days, SFC6 fibroblasts showed 1.346 ± 0.085 μ g GAGs/μ g DNA, while treated 
fibroblasts presented between 1.075 and 1.235 μ g GAGs/μ g DNA. SFC7 fibroblasts had 0.953 ± 0.049 μ g 
GAGs/μ g DNA without treatment, and between 0.812 and 1.168 μ g GAGs/μ g DNA after treatment. After 
seven days, SFC6 fibroblasts showed 1.824 ± 0.136 μ g GAGs/μ g DNA, while treated fibroblasts presented 
between 1.538 and 1.701 μ g GAGs/μ g DNA. SFC7 fibroblasts had 1.521 ± 0.081 μ g GAGs/μ g DNA with-
out treatment and between 1.354 and 1.677 μ g GAGs/μ g DNA after treatment. After 14 days, SFC6 
fibroblasts showed 3.259 ± 0.085 μ g GAGs/μ g DNA, while treated fibroblasts presented between 2.618 
and 2.945 μ g GAGs/μ g DNA. SFC7 fibroblasts had 2.569 ± 0.049 μ g GAGs/μ g DNA without treatment 
and between 1.973 and 2.66 μ g GAGs/μ g DNA after treatment. In general, patients’ storage decreased at 
each time point, reaching a maximum reduction of 24% for siRNA si4901 at 14 days in the fibroblasts of 
patient SFC7. GAG levels in WT fibroblasts were 0.796 ± 0.105 throughout the experiment.
Heparan sulfate storage was evaluated through immunocytochemistry. Clear differences between 
WT and patients’ fibroblasts were observed after cells were fixed and stained with anti-HS antibodies 
(Fig. 3A). After a 3-day treatment with siRNA 4899 (as described above), patients’ fibroblasts showed a 
clear reduction in HS accumulation (Fig. 3B,C). siRNA 4899 was chosen for this experiment because it 
was the one that gave the best results in the reduction of GAG synthesis (see Fig. 1).
Discussion
At present there is no effective treatment for Sanfilippo syndrome. In this report, different siRNAs were 
tested as SRT to inhibit key genes for HS synthesis in Sanfilippo C patients. A similar strategy has been 
applied previously, using shRNAs to inhibit EXTL genes7 and siRNAs to inhibit other genes participating 
in GAG synthesis6.
The siRNAs used in this study showed high mRNA inhibition capacity (around 90%) for as long 
as 14 days at low concentrations (10  nM). This is quite surprising, since we observed a relative loss of 
inhibition of the GAPDH gene (from 90% at day 3 to 60% at day 14, not shown). This long-lasting effect 
on the EXTL genes could be explained by their lower level of expression related to the GAPDH gene 
(less amount of siRNA would be enough to keep EXTL mRNA levels low). Besides, these new generation 
siRNAs are modified to achieve higher stability. Higher concentrations did not improve the result (data 
not shown), indicating the high efficiency of these siRNAs. These inhibition rates were higher than those 
previously obtained for the same genes with shRNAs7.
The results for GAG synthesis were interesting. After three days of transfection, all siRNAs achieved 
notable decreases in the synthetic pathway in both patients. Moreover, the reduction may have been 
even higher, considering that HS synthesis was inhibited but all types of GAG synthesis were quantified. 
Compared with previous results6,7, the higher mRNA inhibition levels obtained here achieved greater 
GAG synthesis inhibition. Another important point to note is that EXTL2 inhibition seemed to be more 
efficient in decreasing GAG synthesis both in our study and in the study by Kaidonis et al.7, suggesting 
Figure 2. Decrease in GAG storage. SFC6 and SFC7 fibroblasts were transfected with all four siRNAs and 
a negative control siRNA and after 3, 7 and 14 days, GAG storage was analysed. Results for both patients are 
the mean ± standard error of three experiments performed in duplicate and are expressed in μ g GAGs/μ g 
DNA at 3 days, 7 days and 14 days after transfection. Differences between EXTL siRNAs respect to negative 
control siRNA were evaluated using the non-parametric Mann-Whitney U test, and statistical significance 
was set at p < 0.05 (*) or p < 0.01 (**).
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that EXTL2 may be a better target candidate. It should be noted that at 7 and 14 days after transfection 
GAG synthesis was decreased in untreated cells, probably due to the fact that they reached conflu-
ence, which may have promoted a decrease in the synthetic pathway of extracellular matrix components 
such as GAGs. It would be interesting to be able to work with more suitable cell types – neural cells, 
for example - which are highly relevant to this disease, and have lower growth rates that would allow 
long-term studies.
Patients’ fibroblast cultures showed a pronounced increase in GAG storage with time, since these cells 
are not able to degrade HS. A slight decrease in storage has been detected after treatment with some of 
the siRNAs. The best results were observed at 14 days, although a trend towards a reduction was detected 
from three days of treatment onwards. We stress, again, that we decreased HS storage but quantified all 
GAG amounts, which may have led to an underestimation of the reduction. In this regard, when HS 
accumulation in the ECM was evaluated by immunocytochemistry, using HS-specific antibodies, a clear 
reduction of the accumulation was observed after three days of treatment.
Taken together, our results indicate that these siRNAs promote a reduction in mRNA levels of target 
genes, a notable reduction in the GAG synthetic pathway after 3 days, specifically of HS, as shown by 
immunocytochemistry, and a slower accumulation rate in patients’ cells over two weeks. Although fur-
ther research is needed, RNAi-based therapies is a promising approach, probably to be used as a com-
plementary therapy to obtain synergic effects with other treatments in order to accelerate the rate of HS 
degradation and/or excretion out of the cell. The search for novel shRNAs, stable and highly inhibitory 
for EXTL2 (the best target, according to our results and those of other authors) is a necessary next step 
on the way to achieving a successful SRT for Sanfilippo syndrome.
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